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Nephritic factor: Description of a new quantitative assay and
findings in glomerulonephritis. A sensitive, quantitative test for
nephritic factor (NF) in human serum is reported. The test is based
on the capacity of NF to initiate fluid phase consumption of the
third complement (C) component in the presence of magnesium
ions (Mg) and of factors of the alternative pathway of C activa-
tion. These factors as well as C3 and C5 were supplied by the
incorporation of normal human serum (NI-IS) into the assay mix-
ture. In order to prevent C3 (and C5) consumption via the Ca-
and Mg-dependent classical pathway, the test was performed in
the presence of the chelating agent Mg-ethylene bis (oxyethylene-
nitrilo) tetraacetic acid (Mg EGTA) which interacts preferentially
with Ca. The Mg EGTA concentration was found to be critical,
a final concentration of 5 mi in the assay mixture being required
for optimal results. By its heat stability (54° to 56°C, 30mm NF
could be distinguished from other, heat-labile NF-like factors.
The NF test was applied to five categories of patients with
glomerulonephritis (GN). Heat-stable NF activity was found in
seven of 17 sera in the membranoproliferative glomerulonephritis
(MPGN) group. Two of the 12 acute poststreptococcal GN sera
had N F-like activity which disappeared upon heating. Serum C3
and proactivator (PA) concentrations varied widely in all groups
but a clear positive relationship was found between the presence of
NF and low serum C3 concentrations in MPGN. Renal immu-
nofluorescence in MPGN indicated a lesser amount of lg deposited
in glomeruli from patients with NF when compared to the NF-
negative patients. Both groups had heavy C3 deposits. The avail-
ability of a sensitive, quantitative assay for NF may help to provide
further insight into the various pathogenic mechanisms in different
forms of MPGN.
Facteur néphritique: Description d'un nouveau dosage quantitatif
et constatations dans les glomérulonéphrites. Un dosage quantitatif
et sensible du facteur néphritique (NF) dans Ic serum humain est
décrit. Le dosage repose sur Ia eapacité de NF d'initier Ia con-
sommation en phase liquide du troisième composant due corn-
plément (C) en presence d'ions magnesium (Mg) et des facteurs
de Ia voie alterne d'activation du complement. Ces facteurs, de
même que C3 et CS, sont fournis par l'adjonction de serum humain
normal (NHS) au milieu de reaction. Pour empêcher Ia con-
sommation de C3 (et de CS) par Ia voie classique Ca et Mg
dépendante le dosage est réalisé en presence du chélateur Mg-
éthylène bis (oxyethylènenitrilo) acide tetra-acétique (Mg EGTA)
qui interagit préférentiellement avec II a été constaté que Ia
concentration de Mg EGTA est critique, une concentration finale
de 5 mrvt dans Ic milieu de reaction est nécessaire pour des rCsultats
optimaux. NF peut être distingué des autres facteurs semblables
mais thermolabiles par sa stabilité a Ia chaleur (54° a 56°C, 30
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mm). Le dosage de NF a été utilisé dans cinq groupes de malades
atteints de glomerulonephrites (GN). Une activité NF thermos-
table a été trouvée dans Ic serum de 7/17 sujets du groupe des GN
membrano-prolifératives. Le serum de deux des douze sujets atteints
de ON aiguë post-streptococcique a montré une activité semblable
a NF mais qui a disparu après chauffage. Les concentrations de C3
et de pro-activateur (PA) étaient variables dans tous les groupes,
cependant une correlation positive nette a été constatée entre Ia
presence de NF et des concentrations basses de C3 dans Ia MPGN.
L'immunofluorescence du tissu renal dans Ia MPGN a montré une
moindre quantité d'Ig déposée dans les glomerules des malades qui
avaient Ic facteur NF par comparaison aux malades NF négatifs.
Les deux groupes avaient des dépôts importants de C3. La dis-
ponibilité d'un dosage sensible et quantitatif de NF peut aider a
atteindre une meilleure comprehension des divers mécanismes
pathogéniques dans les différentes formes de MPGN.
Hypocomplementemia is prominent in some types
of human glomerulonephritis (GN) [1, 2]. It has been
attributed to the consumption of complement (C) by
circulating or tissue-deposited antigen-antibody com-
plexes, or to hyposynthesis and/or hypercatabolism
of individual C proteins [3—5]. An additional mecha-
nism for hypocomplementemia was postulated in
1969 when Spitzer et al [6] described a factor in serum
of patients with GN which in the presence of normal
human serum (NHS) initiated a reaction leading to
the breakdown of C3. This factor was termed C3
nephritic factor (C3NeF, NF). NF was subsequently
shown to act via the alternative pathway of C activa-
tion or properdin system [7] in that it required C3
proactivator (PA) and C3 proactivator convertase
(PAse) in addition to magnesium ions (Mg) for its
effect on C3 [8, 9]. Recent work has established that
NF forms a fluid phase C3 convertase utilizing native
C3, PA, PAse and Mg as cofactors in a manner
similar to but independent of properdin and of the
C3b-dependent feedback mechanism of the alterna-
tive C pathway [10].
The classical C pathway depends on calcium
(Ca) as well as magnesium ions, whereas the alter-
native pathway requires only Mg [11]. Based on
this difference methods have been devised to func-
tionally separate the two pathways. In the presence of
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ethylenediaminetetraacetic acid (EDTA), a strong
chelator of both Ca and Mg, both C pathways
are blocked. However, the addition to NHS of (ethyl-
ene bis [oxyethylenenitrilo]) tetraacetic acid (EGTA),
which has a higher affinity for Ca than Mgil,
blocks the classical pathway while allowing the alter-
native pathway to remain fully operative [121. Using
this approach we have developed a quantitative assay
for activators of the alternative pathway such as NF.
The assay measures by hemolytic titration (effective
molecule titration) the consumption of the third (and
fifth) components of complement (C3 [C51) after in-
cubation of NHS with NF-containing serum. In or-
der to determine the clinical applicability of this assay
for the detection of NF in serum, we have studied
groups of patients with five different types of ON.
Methods
Patient selection. Of the 60 GN patients chosen for
study, all except the 12 patients with acute post-
streptococcal GN were selected from a large popu-
lation of patients from whom renal tissue had been
sent to Scripps Clinic and Research Foundation for
immunopathologic diagnosis. Both immunofluores-
cence and light microscopic data were available for
each biopsy specimen. Patients were categorized as
having either membranoproliferative ON (MPGN),
membranous GN (MGN), systemic lupus erythema-
tosus GN (SLE), anti-glomerular basement mem-
brane antibody-induced ON (A-OBM) or acute post-
streptococcal ON (PSON). A diagnosis of MPGN or
MGN was based solely on the histologic appearance
of the renal biopsy specimen. Ultrastructural analysis
of the kidney biopsy specimens was not available to
further subdivide the MPGN group. SLE was veri-
fied by anti-nuclear antibody determination and by
immunofluorescence microscopy which detected typi-
cal granular deposits of immunoglobulin and C com-
ponents along the glomerular capillary walls and
within some tubules. All A-GBM patients had linear
renal immunofluorescence as well as circulating A-
GBM antibodies as measured by radioimmunoassay
[13]. Serum specimens from patients with PSGN
were kindly provided by Drs. Gerhard Treser and
Alfred Fish. Eighteen healthy laboratory personnel
and six patients chronically ill with various types of
cancer served as controls. Serum samples from
patients studied had been stored at —70°C for peri-
ods ranging from a few weeks to three years. Most of
the samples had been thawed and refrozen prior to
assay. The A-GBM sera had been refrozen several
times.
Immunofluorescence. Renal biopsy tissues were an-
alyzed for the presence of IgO, IgA, 1gM and C3
using fluorescein isothiocyanate (FITC)-coupled
monospecific antisera as previously described [14].
Findings were graded on a semi-quantitative scale
from 0 to 4 with 4 exhibiting the highest degree of
immunofluorescence.
Reagents. 1) Buffers. Veronal-buffered saline con-
taining 1.5 X lO-4M Ca and 5 X 104M
Mg(VBS) was prepared as described [15]. Ve-
ronal-buffered saline (VBS) was prepared similarly
except that the divalent cations were omitted. A solu-
tion of gelatin (G) and ethylenediaminetetraacetic
acid (EDTA) containing VBS (GVBSE), pH 7.4, was
prepared by diluting 0.2M EDTA 1:5 with VBS con-
taining 0.1% gelatin.
2) Mg-ethlene bis (oxyethylenenitrilo) tetraacetic
acid (Mg EGTA). Equal volumes of 0.2 MMg Cl2
prepared by dissolving MgO in 0.4 N HC1 and 0.2M
EGTA, pH 8.5, were mixed to obtain a stock solution
of 0.1M Mg EOTA, pH 7.4. This stock solution was
diluted before use with water as required.
3) EAC4OXY2. Sensitized sheep erythrocytes (EA)
carrying 3000 to 4000 C40''2 sites/cell were prepared
as previously described [16] and were adjusted spec-
trophotometrically to 1.5 X 108 cells/mI.
4) C6-9 reagent. This serum reagent was prepared
as previously described [16]. In brief, to one volume
of fresh guinea pig serum, one volume of 1M KCNS
in water was added in the cold and the mixture was
left 15 to 20 hr at 4°C. Next, hydrazine hydrate was
added to a final concentration of 0.015M and the
mixture was incubated for 45 mm at 37°C. After
dialysis against 2 X 5 liters of cold VBS, the serum
reagent was frozen in aliquots at —70°C. It was di-
luted 1:50 with OVBSE before use. Only freshly
thawed and diluted C6-9 reagent was used.
5) Total complement activity (CH5O). This was de-
termined by a modification of a standard hemolytic
technique [15].
6) Activating substances. Aggregated human y-
globulin (AHGG) was prepared from Cohn fraction
II (Miles Laboratories, Kankakee, Illinois) by heat-
ing for 30 mm at 63°C at a protein concentration of 5
mg/ml of VBS. Any precipitate was removed by
centrifugation for 15 mm at 3000 X g.
Inulin (Pfanstiehl Laboratories, Waukegan, Il-
linois) was suspended in VBS to a concentration of
10 mg/ml.
7) Quantitation of serum C3 and PA. These com-
ponents were measured by single radial immunodif-
fusion using monospecific antisera [17]. The normal
mean values (tg/ml) and the range obtained in this
laboratory are 1239 (1104 to 1373) for C3 and 190
(143 to 226) for PA. Since some sera had been refro-
zen prior to assay, C3 and PA fragments may have
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been generated in some instances increasing the ap-
parent levels of these components.
NF assay. The assay is based on the capacity of NF
to form, together with normal serum co-factors [10],
a C3 convertase whose action results in C3 consump-
tion. NF can therefore be measured by the loss of
hemolytic activity of C3, assayed by the effective
molecule titration [16], after incubation of NF-con-
taming serum with fresh normal serum. Because of
the fluid phase conditions used, little C5 consumption
occurs. This eliminates the need for the addition of
isolated CS during the hemolytic titration. However,
in a strict sense, the method used evaluates both C3
and CS and is therefore referred to as C3 (C5) titra-
tion. Since the generation of the N F-dependent en-
zyme requires only Mg, Mg EGTA is used to block
the classical pathway which depends on both Ca
and The assay procedure is outlined in the
diagram in Fig. 1. It is performed by mixing 0.02 ml
of the serum to be tested for NF and 0.01 ml of
0.025M Mg EGTA in 1 ml conical polystyrene tubes
(Fisher Scientific Cat. No. 4-978-145). Two-hun-
dredths milliliter of NHS is then added and the tubes
are incubated at 37°C. After 30 mm the reaction is
stopped by the addition of 1 ml of ice-cold GVBSE.
The appropriate further dilution of this serum mix-
ture for the effective molecule titration of its C3 (C5)
content is determined by a prior titration of 0.04 ml
of NHS (undiluted and diluted 1:2 with GVBS)
which had been incubated for 30 mm at 37°C with
0.01 ml of 0.02M Mg EGTA. From the two values
obtained, the serum dilution which will result in 60 to
80% lysis in the hemolytic assay can be estimated.
Usually it is between 1: 100 and 1:200. The effective
molecule titration of C3 (CS) is performed by in-
cubating 0.2 ml of the diluted serum mixture with 1.2
ml of the C6—9-.containing reagent and 0.1 ml of
EAC4OXY2 at 37°C [16]. After 60 mm the tubes are
centrifuged for 2 mm in a tabletop centrifuge and
the free hemoglobin is determined spectrophoto-
metrically at 412 nm. The percent consumption of
C3 (CS) is calculated from the total C3 (C5) avail-
able determined from a tube in which the Mg EGTA
had been replaced by 0.04 M EDTA to block any C3
(CS) consumption by either pathway. NF activity is
expressed in U/mI, 1U being that amount of NF-
containing serum which is required to consume 50%
of the total available C3 (C5) in the assay mixture.
Values for NHS in the NF assay were obtained with
serum from 12 healthy laboratory personnel. They
were tested in duplicate on three separate occasions.
The mean percent consumption of C3 (CS) by these
sera was 8.28 12.88 (2 SD). Therefore, all patients'
sera showing more than 21.16% consumption were
Percent 37°C 60 mm C6-9_
C3 (C5) consumption EAC4, 2
Fig. 1. Flow diagram of the nephritic factor (NF) assay. Details are
given in the text.
defined as NF-positive. NF titrations were performed
with those sera which gave more than 50% consump-
tion when used undiluted, i.e., contained more than
SO U of NF/ml.
Results
Influence of Mg EGTA on C3 (C5) consumption by
AHGG and mu/in. The effect of the Mg EGTA con-
centration on the C3 (CS) consumption by AHGG,
an activator of the classical pathway, and by inulin,
an activator of the alternative pathway, was deter-
mined (Table 1). Incubation mixtures consisted of
0.02 ml of NHS; 0.02 ml of AHGG, inulin or VBS;
and 0.01 ml of Mg EGTA. At a final Mg EGTA
concentration of S X lO-3M, addition of AHGG to
NHS led to 9% C3 (CS) consumption as compared to
12% in the control which had received VBS. The use
of inulin, however, resulted in 42% C3 (CS) consump-
tion. At lower or higher Mg EGTA concentrations,
C3 (CS) consumption by AHGG is evident. Con-
sumption at 2 X lO-3M Mg EGTA probably reflects
insufficient chelation of Ca. Whether C3 (CS) acti-
vation by AHGG in the presence of 2 X l03M Mg
EGTA is due to the triggering of the classical or the
alternative pathway is presently unknown. A Mg
C3
Mg EGTA, X l0 AHGGb
(C5) consumption, %
Inulinc VBS
2
5
10
20
VBS++d
22
9
16
29
49
38
42
54
35
48
5
12
16
11
2
1. Test serum
2. M9EGTA
3. NHS
37°C,30mmn NF-induced(20il) C3 (C5) consumption
dilute
Table 1. Influence of Mg EGTA on C3 (CS) consumption inhuman
serum by aggregated human gamma-globulin (AHGG) and inulin
Final concentration in reaction mixture.
b0.625 mg/mI reaction mixture.
4 mg/mI reaction mixture.
d VBS = veronal-buffered saline containing 1.5 X
S X l0'M Mg4.
104M Ca and
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EGTA concentration of 5 X l0-3M was adopted for
all following experiments to avoid the somewhat
higher background observed at 10 X 103M and
higher concentrations of EGTA, which also has been
noted by others [18, 19].
The use of particulate-activating substances such
as inulin leads to the activation and consumption of
both C3 and CS [7]. A decrease in C5 hemolytic
activity was therefore assumed for this experiment as
well but its contribution to the measured consump-
tion of C3 (C5) was not determined.
The influence of preheating of serum on the NE
assay. Early during this study, patients' sera were
routinely heated for 30 mm at 56°C to eliminate any
possible contribution of heat-labile factors. It was
soon found that some of the NF-negative sera be-
came positive as a consequence of the heating pro-
cedure. To substantiate this observation, 12 normal
sera were heated on three occasions at both 56°C and
54°C for 30 mm before undergoing tests for NF and
C (CH5O). After exposure to 54°C, all sera remained
negative in the NF assay; however, after heating at
56°C, eight of 12 became NF-positive with a mean
percent consumption of 32 + 11%. There was no
difference in the degree of inactivation of whole C
which was virtually complete after heating at either
temperature.
Studies of patients with glomerulonephritis. Of the
five different categories of GN studied, we found
properdin system-activating capacity only in the sera
of patients with MPGN and PSGN (Table 2). Seven
of 17 MPGN sera (41%) and two of 12 PSON (17%)
were positive. All seven NF-positive MPGN sera had
heat-stable (54°C) activity. In one instance, when
freshly frozen ACD plasma from one of the seven
patients who also suffered from partial lipodystrophy
was assayed [20], NF activity was found to be heat-
labile. However, in the patient's serum or after purifi-
cation from her plasma, NF activity proved to be
heat-stable. The cause for these differences is pres-
ently not understood. Both NF-positive PSGN sera
had heat-labile activity. This fact suggests the pres-
ence in these sera of an active principle differing from
heat-stable NF. No attempts were made to further
characterize this activity. NF activity was not found
in the sera of 18 normal individuals and six patients
with various types of cancer but without clinically
apparent nephritis.
Correlation of NF activity with the serum concentra-
tions of C3 and PA. Figure 2 lists the C3 and PA
concentrations in the sera of all patients studied.
Varying C3 values were found in all five groups of
ON. Whereas one of the two PSGN patients with
N F-like activity had a near normal serum C3 concen-
tration, the presence of heat-stable NF activity in the
MPGN group was invariably associated with low
concentrations of C3. Serum PA concentrations var-
ied widely and did not show any clear correlation
with the presence or absence of NF activity or with
the C3 concentrations. NF activity in the MPGN pa-
tients varied widely from less than 50 U/ml to more
than 1500 U/ml and variations in NF activity levels
could be detected in individual patients (Fig. 3).
Correlation of renal immunofluorescence with the
presence or absence of NE in MPGN. In general, NF-
positive MPGN patients showed lesser quantities of
granular immunoglobulin deposits in their glomeruli
than their NF-negative counterparts; however, both
groups had heavy glomerular C3 deposits (Table 3).
These findings are consistent with two modes of renal
C3 deposition, one following the alternative C path-
way, the other being secondary to immune complex-
initiated classical C pathway activation. Serial biopsy
specimens were available in two of the NF-positive
patients. In patient 2 an immune complex type of
glomerular injury appeared to be surmounted by per-
sisting C3 deposition, suggesting a perpetuating role
of C in the renal damage as has been noted previously
[21]. In patient I, who had the highest NF levels,
immunofluorescence revealed an increase in pre-
sumed immune complex deposits over time suggest-
ing that NF-associated chronic C3 activation may in
some way have predisposed to glomerular immune
complex localization.
Discussion
NF activity in whole serum has heretofore been
detected by mixing the patients' serum with a normal
reference serum and measuring the resulting reduc-
tion in total hemolytic C [9, 22]. Other methods
involve the detection of the loss of the B antigen of
native C3 [6, 8] or the direct demonstration of C3 or
Table 2. Presence of nephritic factor in serum from patients with GN
MPGN MGN PSGN SLE A-GBM Contro1
Positive/studied, N/N 7/17b 0/10 2/12° 0/15 0/6 0/24
Eighteen normal individuals and six cancer patients.
NF activity heat-stable (54°C, 30 mm).
NF activity heat-labile (54°C, 30 mm).
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PA cleavage products by standard immunoelec-
trophoresis or crossed immunoelectrophoresis [1,
231. A more recently described method of NF detec-
tion depends upon the NF-induced lysis of gluta-
thione-treated human erythrocytes which are
uniquely sensitive to fluid phase C activation [24].
The assay described here is based on the sensitive
hemolytic titration of effective C molecules and con-
stitutes a rapid, quantitative assay for NF activity.
Activation of the alternative pathway by soluble acti-
vators such as NF results in little CS consumption
[7]. This feature allows titration of C3 without adding
isolated CS to the assay mixture. However, whenever
particulate-activating substances are used, C5 con-
sumption will occur and might contribute to the loss
of activity measured by the hemolytic titration
method adopted for the NF assay. Mg EGTA has in
the past been used to distinguish between reactions
involving the classical and the alternative pathways
of C activation [1, 11, 12, 19]. Our results indicate
that the final Mg EGTA concentration is critical in
that too low a concentration only partially blocks the
classical pathway whereas concentrations greater
than 5 X lO-3M again lead to C3 (CS) consumption
by aggregated human y-globulin which is usually
regarded as a classical pathway activator. It therefore
seems to be essential to determine the precise amount
of Mg EGTA necessary for each of the various assays
currently in use. It has been reported that an increase
in the magnesium ion concentration alone suffices to
activate the alternative pathway [18, 19]. Under the
conditions chosen for the NF assay reported here,
evidence for C3 (C5) activation or consumption by
Mg EGTA alone was not obtained (Table 1). Pre-
vious studies have employed heated serum in assays
for NF activity and in one report the heat lability of
the active principle was regarded as a distinctive
property of NF and was used to differentiate between
NF an'd other activators [25]. Our findings indicate
that heating serum to 56°C prior to the NF assay
may lead to false positive results. Therefore, if the
l0
Amount of serum, I
Fig. 3. Quantitation of NE in the serum of a patient with MPGN.
Two serum samples, taken 24 months apart, were assayed. The
dilution of the patient's serum (0.02 ml) used in the test is ex-
pressed on the abscissa in microliters of undiluted serum. The
ordinate indicates the degree of C3 (C5) consumption. The volume
of serum required for 50% consumption (y/l — y = 1)contains 1 U
of NF. Thus, the serum obtained in March, 1973 (• •) con-
tained 555 U of NF/mI; the serum from March, 1975 ( •)
contained 91 U of NF/ml.
Fig. 2. Serum C3 and PA concentrations in
NF-positive (A) and NF-negative (•) Pa-
tients with GN. The shaded areas indicate
the normal ranges of C3 and PA, respec.
tively. Both NF-positive PSGN patients
had heat-labile activity.
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Table 3. Glomerular immunofluorescence findings in NF = positive
and negative MPGN patients
Glomerular immunofluorescence
Patient No.
deposits
IgG IgA 1gM C3
NF = positive patients
1 Istbiopsy Tr 0 0 1—2+
2nd biopsy 25 2+ 2+ 2+ 2—3+
months later
2 lstbiopsy 1+ 0 1+ 4+
2nd biopsy 6 0 0 Tr - 2+
months later
3 0—Tr 0 0 2—3+
4 0 0 0 4+
5 0 0 Tr 2+
6 2+ 3+ 1+ 4+
7 0 0 0 3+
NE = negativepatients
8 1—2+ 1+ 1—2+ 1—2+
9 Tr—+ 1—2+ 0 Tr—l+
10 2+ 2+ 2+ 2+
11 0—Tr 0—Tr 0—Tr Tr—1+
12 3+ 0 1+ 3+
13 3+ 2+ 2+ 2+
14 1—2+ 0 0 1—2+
15 3+ 0 1+ 3+
16 3+ 0 T
0 0
3+
17 0 3+
Graded on a 0 to 4+ scale. When more than one value is given,
it denotes variability from glomerulus to glomerulus. Tr = Trace.
elimination of heat-labile factors is desired, a temper-
ature not higher than 54°C must be utilized. The
studies in this laboratory have established that NF is
stable when subjected to 56°C for 30 mm whether
present in serum or in isolated form. It is of interest
that in one instance the NF activity in the plasma of
an MPGN patient was completely abolished by heat-
ing for 30 mm at 54°C but was not affected when
serum was tested or after the factor had been partially
purified from plasma.
The NF assay we have outlined is based on the
ability of NF to activate the alternative pathway of C;
thus, this assay is not strictly specific for NF. This is
also true of all other described methods for the detec-
tion of NF. Other substances in the patient's serum
which might activate C in the presence of Mg EGTA
include activated properdin [26], circulating C3b [27,
28], IgA aggregates [29, 30] and, possibly, endotoxin
[31, 32]. However, there is strong indirect evidence
that the NF assay was indeed detecting NF. Schreiber
et al [10] passed the NF purified from one of the
MPGN patients over an anti—properdin—immune
absorbent column which removed all the properdin
but did not alter the NF titer of the preparation;
therefore, in this patient, the NF activity could not be
ascribed to properdin. C3b is rapidly degraded by
C3b inactivators (C3b INA) and does not normally
accumulate in the circulation [33]. Furthermore,
C3b-dependent activation of the alternative pathway
in serum is inefficient (Schreiber RD, Götze 0, Mül-
ler-Eberhard Hi: in preparation). Analysis of NF
preparations from three patients excluded the possi-
bility that IgA aggregates contributed to the observed
activities. Circulating endotoxin is difficult to exclude
but would seem unlikely to be present in active form
in our patients who had no clinical signs of endotox-
emia or septicemia. Finally, the substance responsible
for the NF activity in three of our patients was par-
tially purified and found to have the physicochemical
and immunochemical properties of NF as previously
defined [9, 10].
We found NF activity only in patients with
MPGN. Other investigators have reported the pres-
ence of C3-activating factor in PSGN [1, 34, 35] and
SLE [35]. However, these activities are probably not
related to NF [35]. Partial lipodystrophy with and
without clinically apparent nephritis has also been
found to be associated with serum NF activity [20,
36—40]. All of our NF-positive patients had low se-
rum C3 concentrations while only one showed de-
pressed serum PA (Fig. 2). A similar correlation was
observed by Williams et al [1].
The variable relationship between NF and gb-
merular deposition of immunoglobulin and C3 in this
and other studies makes it difficult to evaluate the
role of NF in nephritis. Rather, N F-assOciated com-
plement activation appears to be intertwined with the
major immunopathogenic mechanism of glomerular
injury, namely the deposition of circulating immune
complexes. NF-induced C3 activation could then ei-
ther follow and possibly perpetuate an immune com-
plex-initiated injury or in other instances precede and
in some as yet unknown way predispose to gbomeru-
lar injury by immune-complex deposition [39], This
latter possibility has to be considered in patient 7 who
had a long history of partial lipodystrophy. Nephritis
was not suspected until NF was found in her serum;
only then did a renal biopsy establish a diagnosis of
MPGN [20]. The presence of at least two forms of
MPGN based on ultrastructural criteria, C serum
profiles and immunofluorescence studies [41] further
emphasizes the complexity of this clinical entity.
At this point the evidence for a direct role of NF in
the pathogenesis of nephritis is merely circumstantial.
The presence of multiple, unrelated factors in serum
containing NF-like activity has contributed to the
uncertainties surrounding any role for NF. Until a
specific test for NF becomes available, the use of
sensitive, quantitative assays for NF such as that
described here may help to clarify the role of NF in
renal disease.
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